(Total Views: 610)
Posted On: 12/23/2020 10:33:36 AM
Post# of 154376
“By the way, Mesoblast said that the improved care was responsible for the reduction of deaths and failure of their effort.”
What’s interesting about the Mesoblast trial, when comparing it to the leronlimab S/C trial, is that Mesoblast at the 50% interim analysis, like CYDY, was told to continue the trial with no modifications. Unfortunately for Mesoblast, at the 75% interim analysis, the DSMC determined that contouring the trial to full enrollment was futile due to the reasons listed in their PR. Trials can change quickly, especially when mortality is the primary endpoint.
What’s interesting about the Mesoblast trial, when comparing it to the leronlimab S/C trial, is that Mesoblast at the 50% interim analysis, like CYDY, was told to continue the trial with no modifications. Unfortunately for Mesoblast, at the 75% interim analysis, the DSMC determined that contouring the trial to full enrollment was futile due to the reasons listed in their PR. Trials can change quickly, especially when mortality is the primary endpoint.
(1)
(0)
